EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

NexturnBioscience Co. Ltd (089140) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of NexturnBioscience Co. Ltd KRW 1,739, price KRW 2,160, upside -19.5%, quality 27 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Industrials · KR · ISIN KR7089140008

NC Thin data Oct 3, 2026

NexturnBioscience Co. Ltd

089140 · KQ

Weak valuationQuality is weak on top of the rich price.

Low debt
Expensive Growth (revenue 5y +48.7 %/yr in KRW)
Thin margins · 9.8% net margin (TTM)
Fair value 1,739 KRW · Overvalued (−19.5%)
Quality 27/100
Negative free cash flow
Trails peers (2/7)
Narrow moat 21/100
Thin data
⚠ Dilution
Watch NexturnBioscience Co. Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

56,500 KRW 1,853 KRW Fair Value 1,739 KRW Apr 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 3, 2026.

How to read this chart

60‑month range 1,853 KRW – 56,500 KRW · fair‑value band 1,621 KRW – 1,838 KRW · the 2,160 KRW price screens above the 1,739 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 3, 2026.

Follow NexturnBioscience Co. in your weekly email

Every Wednesday you see whether NexturnBioscience Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Nexturn Co.,Ltd. develops and produces CNC automatic lathe machines in Korea and internationally. It provides CNC swiss-type automatic lathe products, high temperature display glass press equipment, and automatic line-up robots, as well as an intelligent intervention robot system based on robot 3D cardiovascular visualization technology.

Show more

Nexturn Co.,Ltd. develops and produces CNC automatic lathe machines in Korea and internationally. It provides CNC swiss-type automatic lathe products, high temperature display glass press equipment, and automatic line-up robots, as well as an intelligent intervention robot system based on robot 3D cardiovascular visualization technology. The company was formerly known as KMT Incorporated and changed its name to Nexturn Co.,Ltd. in April 2004. Nexturn Co.,Ltd. was founded in 2000 and is based in Yongin, South Korea.

Stock analysis

NexturnBioscience Co. Ltd (089140) currently trades at 2,160 KRW, while our model-based Fair Value estimate is 1,739 KRW, 19.5% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Asset-Based group reads highest at a median of 6,071 KRW per share, and 6 of the 6 models we run sit above the 2,160 KRW price.

Bear case: the Earnings-Based group reads lowest at 2,213 KRW, and 0 of the 6 models stay below the price. Evidence for this calculation is low.

Scenario range: 1,621 KRW (bear) to 1,838 KRW (bull), the price of 2,160 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 27/100 (below-average quality), in the Industrials sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

NexturnBioscience Co. Ltd reported revenue of 70.4B KRW in FY2025 versus 17.0B KRW in FY2021, a compound +42.7%/yr. Reported net income was −9.7B KRW in FY2025.

Key figures

Market cap 32.2B KRW (≈ $24.0M) · P/S ratio 1.61 · Net margin −13.8% · Return on equity −1,091% · Return on assets (EBIT) −3.7% · Operating margin −16.8% · Revenue growth (YoY) +237% · EPS growth (YoY) −11.3%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (low confidence).

What moves the price

The share trades about 28% below its 52-week high and 17% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Industrials peers we cover trades at 8% fair-value upside, at −19%, 089140 screens richer than that median.

Fair Value models

Bear 1,621 KRW Fair Value 1,739 KRW Bull 1,838 KRW
Price 2,160 KRW · Upside -19.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
EPV 2,034 KRW 2,213 KRW 2,367 KRW 72
ROIC Compounder 2,034 KRW 2,213 KRW 2,367 KRW 71
EV/EBITDA 4,374 KRW 5,531 KRW 6,688 KRW 66
All 6 models by family
Earnings-Based
EPV 2,034 KRW 2,213 KRW 2,367 KRW 72
Multiples
EV/EBIT 2,863 KRW 3,516 KRW 4,170 KRW 65
EV/EBITDA 4,374 KRW 5,531 KRW 6,688 KRW 66
EV/Revenue 2,301 KRW 2,901 KRW 3,501 KRW 53
Asset-Based
NCAV (Graham) 4,531 KRW 6,071 KRW 9,061 KRW 52
Economic Profit
ROIC Compounder 2,034 KRW 2,213 KRW 2,367 KRW 71

Open the full fair value analysis →

Notify me when 089140 reaches fair value

Put 089140 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 27/100

Of which business quality 26 · Market factors (momentum, volatility) 28

Profitability 5
Margins and returns on capital today
Quality Growth 93
Are margins and returns improving?
Cashflow 0
Earnings quality: real cash, not paper profit
Fin. Strength 28
Balance sheet, leverage, solvency risk
Investment 55
Disciplined investing over empire-building
Low Volatility 20
Calm price path (market factor)
Momentum 35
Price trend over the last 3–12 months (market factor)
52W Momentum 25
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 58/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+122.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+44.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+48.7%
Start year 2020 (pandemic). Over 10 years: +15.8% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.9%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
9.2% (2019) → −67.7% (2024)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

089140 screens overvalued: fair value 19% below the price. Compare with Sungho Electronics Corp →

Compare NexturnBioscience Co. Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Machinery, Tools, Heavy Vehicles, Trains & Ships · 43 stocks

Beats the industry median on 2/7 measures
Overall it trails its industry peers.
Valuation
Quality Score 27 · Bottom 25%
Fair Value upside −19.5% · Below median
Profitability
Return on assets −1.2% · Bottom 25%
Net margin (TTM) 9.8% · Above median
Operating margin (TTM) −16.8% · Bottom 25%
Growth and dividend
Revenue growth 237.3% · Top 25%
Balance sheet
Debt / equity 0.05× · Above median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)7 · sector 45
FUTURE (revenue growth)100 · sector 54
PAST (return on equity)0 · sector 100
HEALTH (low debt)98 · sector 99
DIVIDEND (yield)0 · sector 36

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Machinery, Tools, Heavy Vehicles, Trains & Ships stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Sungho Electronics Corp 043260 26,450 KRW 4,624 KRW −83%
BHI Co 083650 60,300 KRW 66,330 KRW +10%
VITZROCELL Co 082920 28,150 KRW 30,965 KRW +10%
Tae Kwang Corporation 023160 27,700 KRW 14,672 KRW −47%
Bosung Power Technology Co 006910 7,400 KRW 8,549 KRW +16%
Hanla IMS Co 092460 16,790 KRW 22,442 KRW +34%
Neo Technical System Co 085910 17,120 KRW 5,882 KRW −66%
LOT VACUUM Co 083310 11,980 KRW 4,699 KRW −61%
Komelon Corporation 049430 22,600 KRW 22,215 KRW −2%
BMT Co 086670 19,050 KRW 20,568 KRW +8%

Explore undervalued stocks

More undervalued Industrials stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

NexturnBioscience Co. Ltd · Fair Value
1,739 KRW −19%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "NexturnBioscience Co. Ltd Fair Value". https://www.fairvalue-calculator.com/stock/089140

Frequently asked questions

Is NexturnBioscience Co. Ltd (089140) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of 1,739 KRW versus a price of 2,160 KRW, about −19% upside (overvalued).
What is the fair value of 089140?
Our model-based fair value for NexturnBioscience Co. Ltd is 1,739 KRW (as of Oct 3, 2026), built from audited fundamentals. The current price: 2,160 KRW.
What is the quality score of 089140?
NexturnBioscience Co. Ltd has a Quality Score of 27/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for NexturnBioscience Co. Ltd (089140)?
Our model-based price target is the fair value of 1,739 KRW (as of Oct 3, 2026) from 6 valuation models. Cautious scenario 1,621 KRW, optimistic scenario 1,838 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the NexturnBioscience Co. Ltd stock forecast for 2026?
Our models put fair value at 1,739 KRW, about −19% upside versus a price of 2,160 KRW (overvalued). Cautious scenario 1,621 KRW, optimistic scenario 1,838 KRW. The calculation is refreshed regularly with new filings.
What is the intrinsic value of NexturnBioscience Co. Ltd (089140)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For NexturnBioscience Co. Ltd it is 1,739 KRW per share (as of Oct 3, 2026), against a price of 2,160 KRW. It is the blended result of 6 valuation models (cash flow, earnings, asset, dividend).
Is NexturnBioscience Co. Ltd stock overvalued or undervalued in 2026?
As of Oct 3, 2026, 089140 trades above its calculated fair value: price 2,160 KRW, fair value 1,739 KRW, a gap of about −19% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 089140?
No. The price is what the market pays today (2,160 KRW); the fair value is what the company's own numbers justify (1,739 KRW). For NexturnBioscience Co. Ltd the two are 420.82 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is NexturnBioscience Co. Ltd worth?
The market values NexturnBioscience Co. Ltd at about 32.2B KRW (market capitalisation, as of Oct 3, 2026). Per share that is 2,160 KRW; our models calculate a fair value of 1,739 KRW per share.
What do the bullish and bearish scenarios say about 089140?
Our models span a range for NexturnBioscience Co. Ltd: cautious scenario 1,621 KRW, base 1,739 KRW, optimistic 1,838 KRW per share (as of Oct 3, 2026, price 2,160 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of NexturnBioscience Co. Ltd (089140)?
Balance-sheet figures for NexturnBioscience Co. Ltd (as of Oct 3, 2026): debt of 0.05 per unit of equity. They feed the Quality Score of 27/100, which measures business quality independently of the share price.
How far is 089140 from its 52-week high?
NexturnBioscience Co. Ltd trades at 2,160 KRW, about 28% below its 52-week high of 2,995 KRW and 17% above the low of 1,853 KRW (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of 1,739 KRW is for.
Which stocks are comparable to NexturnBioscience Co. Ltd?
From the same area (Industrials) we also value Sungho Electronics Corp, BHI Co, VITZROCELL Co, Tae Kwang Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is NexturnBioscience Co. Ltd stock attractive at the current price?
The data as of Oct 3, 2026: price 2,160 KRW, calculated fair value 1,739 KRW (−19%), Quality Score 27/100, from 6 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 089140 calculated?
We run NexturnBioscience Co. Ltd through 6 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 1,739 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.9 % above its aggregate fair value. NexturnBioscience Co. Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of NexturnBioscience Co. Ltd (089140)?
The closing price on Oct 2, 2026 was 2,160 KRW. Our model-based fair value is 1,739 KRW, about −19% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with NexturnBioscience Co. Ltd right now?
The price sits above even our optimistic bull case (1,838 KRW). The favourable scenario is already priced in. Weak quality (27/100) and above fair value at the same time, the margin of safety is missing on both counts. The models converge in a tight band (1,621 KRW to 1,838 KRW), unusually little disagreement for a valuation. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of NexturnBioscience Co. Ltd

How large is the market capitalisation of NexturnBioscience Co. Ltd (089140)?
The market capitalisation of NexturnBioscience Co. Ltd is 32.2B KRW (≈ $24.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of NexturnBioscience Co. Ltd (089140)?
The price-to-sales ratio of NexturnBioscience Co. Ltd is 1.61 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of NexturnBioscience Co. Ltd (089140)?
The net margin of NexturnBioscience Co. Ltd is −13.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of NexturnBioscience Co. Ltd (089140)?
The return on equity (ROE) of NexturnBioscience Co. Ltd is −1,091% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of NexturnBioscience Co. Ltd (089140)?
On an EBIT basis the return on assets of NexturnBioscience Co. Ltd is −3.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of NexturnBioscience Co. Ltd (089140)?
The operating margin of NexturnBioscience Co. Ltd is −16.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at NexturnBioscience Co. Ltd (089140)?
Revenue at NexturnBioscience Co. Ltd is growing +237% versus a year earlier (3y avg +44.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at NexturnBioscience Co. Ltd (089140)?
Earnings per share at NexturnBioscience Co. Ltd are growing −11.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does NexturnBioscience Co. Ltd (089140) generate?
The free cash flow of NexturnBioscience Co. Ltd is −6.2B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does NexturnBioscience Co. Ltd (089140) carry?
The net debt of NexturnBioscience Co. Ltd is 74.5B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch NexturnBioscience Co. Ltd in the live analysis

One click puts NexturnBioscience Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.